ITOS NASDAQ
Watertown, MA 02472-5710
US
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Call Matthew | D-Return | 135,937 | $7.05 | 2025-08-29 |
| Call Matthew | D-Return | 146,835 | $4.24 | 2025-08-29 |
| Call Matthew | D-Return | 66,170 | $2.95 | 2025-08-29 |
| Call Matthew | U-Tender | 161,898 | $10.05 | 2025-08-29 |
| Detheux Michel | D-Return | 52,700 | $6.16 | 2025-08-29 |